Global Schizophrenia Drugs (Orals & Injectables) Market: Insights, Trends and Forecast (2019-2023)

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $1,600	95 Pages	Koncept Analytics	October, 2019	KOAN16064940

Best Price Guarantee
Price	from $1,600
Length	95 Pages
Publisher	Koncept Analytics
Published Date	October, 2019
SKU	KOAN16064940

Global Schizophrenia Drugs (Orals & Injectables) Market: Insights, Trends and Forecast (2019-2023)

The global schizophrenia market is estimated to reach US$10.43 billion in 2023, growing at a CAGR of 3.69%, for the period spanning from 2018 to 2023. The factors such as rising occurrence of schizophrenia, surging chronic ailments incidence, increasing personal healthcare expenditure, accelerating economic growth and unmet medical needs are expected to drive the market growth. However, growth of the industry would be challenged by stringent regulations, patient health-associated risk, associated business risk and limited access to patent rights. A few notable trends include rising pharmaceutical R&D spending, intensifying e-commerce pharmaceutical products sales, progressing schizophrenia drugs pipeline and rising adoption of somatic therapy.

On the basis of mode of administration, schizophrenia market has been segmented into long acting injections and oral. Amongst them, owing to effective long-term relapse prevention, increased patient compliance, ease of administration and reduced hospitalization rates, long acting injections are widely used for managing or treating schizophrenia patients.

The fastest growing regional market is Americas owing to continuous advancement in the second & third generation anti-psychotic drugs, increasing schizophrenia population and development of economical long acting drugs by local manufacturers in US and Canada. The US is the largest market and is already well-penetrated at developed market levels.

Scope of the report:

The report provides a comprehensive analysis of the global schizophrenia market, segmented on the basis of mode of administration i.e. oral & long acting injections, by therapeutic class i.e. second generation & third generation anti-psychotics and drug type i.e. Invega Sustenna, Latuda, Arsitada & Rexulti.
The major regional markets (Americas, Europe and Asia-Pacific) have been analysed, along with country coverage of the U.S, Germany and Japan.
The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.
The competitive landscape of the market, along with the company profiles of leading players (Allergan Plc, Johnson & Johnson, Otsuka Holdings Co., Ltd., Sumitomo Chemical Co., Ltd., Alkermes Plc and Acadia Pharmaceuticals Inc.) are also presented in detail.

Key Target Audience:

Drug Manufacturers
Raw Material Suppliers
End Users
Consulting Firms
Investment Banks
Government Bodies & Regulating Authorities

1. Market Overview: 1.1 Introduction; 1.2 Causes; 1.3 Symptoms; 1.4 Diagnosis; 1.5 Treatment; Table 1: Common Anti-Psychotics Approved for Schizophrenia Treatment
2. Global Schizophrenia Market Analysis: 2.1 Global Schizophrenia Market Value Forecast; Table 2: Global Schizophrenia Market Value Forecast (2018-2023); 2.2 Global Schizophrenia Market Value by Mode of Administration; Table 3: Global Schizophrenia Market Value by Mode of Administration (2018); 2.2.1 Global Long Acting Injections Schizophrenia Market Value Forecast; Table 4: Global Long Acting Injections Schizophrenia Market Value Forecast (2018-2023); 2.2.2 Global Oral Schizophrenia Market Value Forecast; Table 5: Global Oral Schizophrenia Market Value Forecast (2018-2023); 2.3 Global Schizophrenia Market Value by Therapeutic Class; Table 6: Global Schizophrenia Market Value by Therapeutic Class (2018); 2.3.1 Global Second Generation Anti-Psychotic Market Value Forecast; Table 7: Global Second Generation Anti-Psychotic Market Value Forecast (2018-2023); 2.3.2 Global Third Generation Anti-Psychotic Market Value Forecast; Table 8: Global Third Generation Anti-Psychotic Market Value Forecast (2018-2023); 2.4 Global Schizophrenia Market Value by Drug Type; Table 9: Global Schizophrenia Market Value by Drug Type (2018); 2.4.1 Global Invega Sustenna Drug Value Forecast; Table 10: Global Invega Sustenna Drug Value Forecast (2018-2023); 2.4.2 Global Latuda Drug Value Forecast; Table 11: Global Latuda Drug Value Forecast (2018-2023); 2.4.3 Global Aristada Drug Value Forecast; Table 12: Global Aristada Drug Value Forecast (2018-2023); 2.4.4 Global Rexulti Drug Value Forecast; Table 13: Global Rexulti Drug Value Forecast (2018-2023); 2.5 Global Schizophrenia Market Value by Region; Table 14: Global Schizophrenia Market Value by Region (2018)
3. Regional Schizophrenia Market Analysis: 3.1 Americas; 3.1.1 Americas Schizophrenia Market Value Forecast; Table 15: Americas Schizophrenia Market Value Forecast (2018-2023); 3.1.2 The U.S. Schizophrenia Market Value Forecast; Table 16: The U.S. Schizophrenia Market Value Forecast (2018-2023); 3.1.3 The U.S. Schizophrenia Market Value by Mode of Administration; Table 17: The U.S. Schizophrenia Value by Mode of Administration (2018); 3.1.4 The U.S. Long Acting Injections Schizophrenia Market Value Forecast; Table 18: The U.S. Long Acting Injections Schizophrenia Market Value Forecast (2018-2023); 3.1.5 The U.S. Oral Schizophrenia Market Value Forecast; Table 19: The U.S. Oral Schizophrenia Market Value Forecast (2018-2023); 3.2 Europe; 3.2.1 Europe Schizophrenia Market Value Forecast; Table 20: Europe Schizophrenia Market Value Forecast (2018-2023); 3.2.2 Europe Schizophrenia Market Value by Mode of Administration; Table 21: Europe Schizophrenia Value by Mode of Administration (2018); 3.2.3 Europe Oral Schizophrenia Market Value Forecast; Table 22: Europe Oral Schizophrenia Market Value Forecast (2018-2023); 3.2.4 Europe Long Acting Injections Schizophrenia Market Value Forecast; Table 23: Europe Long Acting Injections Schizophrenia Market Value Forecast (2018-2023); 3.2.5 Germany Schizophrenia Market Value Forecast; Table 24: Germany Schizophrenia Market Value Forecast (2018-2023); 3.3 Asia-Pacific; 3.3.1 Asia-Pacific Schizophrenia Market Value Forecast; Table 25: Asia-Pacific Schizophrenia Market Value Forecast (2018-2023); 3.3.2 Japan Schizophrenia Market Value Forecast; Table 26: Japan Schizophrenia Market Value Forecast (2018-2023)
4. Market Dynamics: 4.1 Growth Drivers; 4.1.1 Rising Occurrence of Schizophrenia; Table 27: The U.S. Schizophrenia Patient Population (2014-2018); 4.1.2 Surging Chronic Ailments Incidence; Table 28: Global New Cancer Patients Volume (2014-2018); 4.1.3 Increasing Personal Healthcare Expenditure; Table 29: Global Personal Healthcare Expenditure (2014-2018); 4.1.4 Accelerating Economic Growth; Table 30: Global Gross Domestic Product (GDP) per Capita (2014-2018); 4.1.5 Unmet Medical Needs; 4.2 Key Trends and Developments; 4.2.1 Rising Pharmaceutical R&D Spending; Table 31: Global Pharmaceutical R&D Spending (2014-2018); 4.2.2 Intensifying E-Commerce Pharmaceutical Products Sales; Table 32: Global E-Commerce Pharmaceutical Products Sales (2018-2023); 4.2.3 Progressing Schizophrenia Drugs Pipeline; Table 33: Upcoming Schizophrenia Drugs (2019-2023); 4.2.4 Rising Adoption of Somatic Therapy; 4.3 Challenges; 4.3.1 Stringent Regulations; 4.3.2 Patient Health-Associated Risk; 4.3.3 Associated Business Risk; 4.3.4 Limited Access to Patent Rights
5. Competitive Landscape: 5.1 Global Schizophrenia Market; 5.1.1 Key Players – Revenue Comparison; Table 34: Key Players – Revenue Comparison (2018); 5.1.2 Key Players – Market Cap Comparison; Table 35: Key Players – Market Cap Comparison (2019); 5.1.3 Key Players – Research & Development Expenditure Comparison; Table 36: Key Players – Research & Development Expenditure Comparison (2017-2018); 5.1.4 Key Players – Drug Features Comparison; Table 37: Key Players – Drug Features Comparison (2018)
6. Company Profiles: 6.1 Allergan Plc; 6.1.1 Business Overview; 6.1.2 Financial Overview; Table 38: Allergan Net Revenues and Net Loss (2014-2018); Table 39: Allergan Net Revenues by Segments (2018); Table 40: Allergan Net Revenues by Region (2018); 6.1.3 Business Strategies; 6.2 Johnson & Johnson; 6.2.1 Business Overview; 6.2.2 Financial Overview; Table 41: J&J Sales and Net Earnings (2014-2018); Table 42: J&J Sales by Segments (2018); 6.2.3 Business Strategies; 6.3 Otsuka Holdings Co., Ltd.; 6.3.1 Business Overview; Table 43: Otsuka Holdings Segment Overview; 6.3.2 Financial Overview; Table 44: Otsuka Holdings Revenues and Profit (2014-2018); Table 45: Otsuka Holdings Revenues by Segment (2018); Table 46: Otsuka Holdings Revenues by Region (2018); 6.3.3 Business Strategies; 6.4 Sumitomo Chemical Co., Ltd.; 6.4.1 Business Overview; Table 47: Sumitomo Chemicals Segment Overview; 6.4.2 Financial Overview; Table 48: Sumitomo Chemicals Net Sales and Net Income (2015-2019); Table 49: Sumitomo Chemicals Net Sales by Segments (2019); 6.4.3 Business Strategies; 6.5 Alkermes Plc; 6.5.1 Business Overview; 6.5.2 Financial Overview; Table 50: Alkermes Product Pipeline Overview; Table 51: Alkermes Revenues and Net Loss (2014-2018); Table 52: Alkermes Revenues by Region (2018); 6.5.3 Business Strategies; 6.6 Acadia Pharmaceuticals Inc.; 6.6.1 Business Overview; Table 53: Acadia Pharmaceuticals Product Pipeline Overview; 6.6.2 Financial Overview; Table 54: Acadia Pharmaceuticals Revenues and Net Loss (2014-2018); 6.6.3 Business Strategies